["66 yo patient with previously resected clear-cell renal cell carcinoma, presents now with local unresectable recurrence. genetic testing is notable for vhl and pbrm1 mutations, as well as msi-h. what oprions are recommended for systemic treatment?", "for a patient with nut midline carcinoma and known brd4-nut fusion, is there a targeted therapy for their disease?", "my patient with metastatic or unresectable pancreatic adenocarcinoma has progressed on at least one line of chemotherapy and was found to have an nrg1 gene fusion via somatic tumor testing. what options are there for subsequent treatment?", "what is an acceptable treatment in patients with estrogen receptor-positive, her2-negative, esr1-mutated advanced or metastatic breast cancer who have experienced disease progression following at least one line of endocrine therapy?", "what is a targeted therapy that can be used for the management of patients with relapsed or refractory follicular lymphoma with ezh2 mutation?", "i have a patient with advanced kidney cancer and the primary tumor had a mutation in pbrm1. what is the treatment implication of this mutation", "i have a patient with cdk12 mutated metastatic castrate-resistant prostate cancer which has progressed on adt, abiraterone, and radium. are there any biomarker-directed therapies that he would be eligible for?", "what targeted treatment option is available for patients with high-risk neuroblastoma and an activating alk mutation?", "a patient with localized ewing sarcoma has a stag2 mutation, and has just relapsed. what are reasonable relapse regimens to consider?", "my metastatic cutaneous melanoma patient has high tmb and a braf mutation. what should i do?", "i have a patient with metastatic descending colon adenocarcinoma, that is kras and braf wt, what first line targeted therapy therapy options are there in addition to folfox or folfiri", "if a patient with progressive or metastatic medullary thyroid cancer needs systemic therapy and the tumor has a ret mutation, what is preferred first line treatment?", "for a patient with lung adenocarcinoma and a kras g12c mutation, what targeted treatments are approved and for what stage?", "are alk inhibitors approved for use in tfcp2 fusion positive rhabdomyosarcoma?", "for a patient with relapsed b-all that expresses cd19, what targeted treatment options exist?", "a patient with relapsed high-risk neuroblastoma has alk mutation x. should they receive an alk inhibitor, and if so, which one?", "is there a first line targeted therapy for patients with lung cancer and a ros1 rearrangement?", "in a patient with follicular lymphoma with an activating ezh2 mutation, what treatment is indicated?", "what can target high grade wilms tumor with wt1 mutation", "i have a patient with metastatic cholangiocarcinoma and an fgfr2 fusion. this patient has already progressed on standard first-line treatments. are there any approved therapies i should consider?", "i have a patient with metastatic bladder cancer who has progressed on chemotherapy. genomics testing revealed a focal amplification of the jak2/pd-l1 locus. what are the treatment options?", "for patients with advanced cancer and with high tmb, regardless of cancer types, are there drugs approved?", "what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation", "what drug combination is approved for adults with kras g12c-mutated advanced colorectal cancer who have progressed on chemotherapy?", "i have a patient with metastatic hr-negative, her2-low, pd-l1-negative, breast cancer with no germline brca mutation.  for second line, is t-dxd or sacituzumab govitecan preferred?"]